Terns Pharmaceuticals Files 8-K

Ticker: TERN · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1831363

Sentiment: neutral

Topics: 8-K, regulatory-filing, corporate-events

TL;DR

Terns Pharma dropped an 8-K on Nov 3rd - check it for Reg FD, other events, and financials.

AI Summary

Terns Pharmaceuticals, Inc. filed an 8-K on November 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Foster City, California.

Why It Matters

This 8-K filing provides an update on Terns Pharmaceuticals' corporate activities and regulatory disclosures, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting standard corporate events and disclosures, not indicating any immediate significant financial or operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Terns Pharmaceuticals, Inc.?

The primary purpose is to report on events that require current disclosure, including Regulation FD disclosures, other events, and financial statements and exhibits, as of November 3, 2025.

When was Terns Pharmaceuticals, Inc. incorporated, and where are its principal executive offices located?

Terns Pharmaceuticals, Inc. was incorporated in Delaware, and its principal executive offices are located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.

What is the Commission File Number for Terns Pharmaceuticals, Inc.?

The Commission File Number for Terns Pharmaceuticals, Inc. is 001-39926.

What is the telephone number for Terns Pharmaceuticals, Inc.?

The telephone number for Terns Pharmaceuticals, Inc., including area code, is (650) 525-5535.

What specific items are being reported under the Form 8-K filing by Terns Pharmaceuticals, Inc.?

The filing specifically lists 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits' as items being reported.

Filing Stats: 1,638 words · 7 min read · ~5 pages · Grade level 17.6 · Accepted 2025-11-03 09:13:48

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, issued by Terns Pharmaceuticals, Inc. on November 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: November 3, 2025 By: /s/ Caryn McDowell Caryn McDowell Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing